Skip to main content

. 1995 Jul 29;311(7000):292. doi: 10.1136/bmj.311.7000.292a

Potentiation of warfarin by interferon.

Y Adachi ¹, Y Yokoyama ¹, T Nanno ¹, T Yamamoto ¹

PMCID: PMC2550360 PMID: 7543311

292

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Okuno H., Kitao Y., Takasu M., Kano H., Kunieda K., Seki T., Shiozaki Y., Sameshima Y. Depression of drug metabolizing activity in the human liver by interferon-alpha. Eur J Clin Pharmacol. 1990;39(4):365–367. doi: 10.1007/BF00315411. [DOI] [PubMed] [Google Scholar]
Okuno H., Takasu M., Kano H., Seki T., Shiozaki Y., Inoue K. Depression of drug-metabolizing activity in the human liver by interferon-beta. Hepatology. 1993 Jan;17(1):65–69. [PubMed] [Google Scholar]
Renton K. W., Singh G., Stebbing N. Relationship between the antiviral effects of interferons and their abilities to depress cytochrome P-450. Biochem Pharmacol. 1984 Dec 1;33(23):3899–3902. doi: 10.1016/0006-2952(84)90058-3. [DOI] [PubMed] [Google Scholar]
Smith P., Arnesen H., Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med. 1990 Jul 19;323(3):147–152. doi: 10.1056/NEJM199007193230302. [DOI] [PubMed] [Google Scholar]
Williams S. J., Baird-Lambert J. A., Farrell G. C. Inhibition of theophylline metabolism by interferon. Lancet. 1987 Oct 24;2(8565):939–941. doi: 10.1016/s0140-6736(87)91422-x. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES